Jeselhy pimitespib
Drug Class
HSP90 inhibitorHSP90 抑制剂
Mechanism
Inhibits heat shock protein 90 (HSP90), promoting the destabilization and degradation of oncogenic client proteins such as KIT and PDGFRA.特异性抑制热休克蛋白90 (HSP90) ，促进驱动肿瘤生长的关键致癌靶蛋白（如KIT和PDGFRA）发生不稳定并降解。
Approved Indication
Gastrointestinal stromal tumors (GIST) that have progressed after prior chemotherapy, per its PMDA approval in Japan.根据日本PMDA批准，适用于既往化疗后进展的晚期胃肠道间质瘤（GIST）。
What This Means For Patients
Jeselhy is a first-in-class HSP90 inhibitor approved in Japan for patients with advanced gastrointestinal stromal tumors (GIST) who have developed resistance to standard treatments. It helps destabilize tumor-promoting proteins and is available in Boao Lecheng.Jeselhy是一种新型HSP90抑制剂，在日本被批准用于治疗对常规治疗产生抗性的晚期胃肠道间质瘤（GIST）。它通过促进肿瘤相关蛋白降解来发挥作用，患者可在博鳌乐城特许申请。
Regulatory Approvals
- PMDA — approved (2022) — source
Pivotal Clinical Evidence
- CHAPTER-GIST-301 — Kurokawa et al., Ann Oncol 2022 (JapicCTI-184094) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.